MRI Unlocks Better Treatments for Atypical Parkinsonisms: A Groundbreaking Study
An international study led by researchers from the Sant Pau Research Institute (IR Sant Pau) has revealed a groundbreaking use of magnetic resonance imaging (MRI) that significantly enhances the diagnosis of progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD). These are two rare and often underdiagnosed atypical parkinsonian disorders. The study, published in The Journal of Prevention of Alzheimer's Disease, demonstrates that this advanced MRI technique not only improves early diagnosis but also revolutionizes the design of clinical trials, making them more precise and feasible for diseases without current disease-modifying treatments.
Dr. Jesús García-Castro, a researcher in the Neurobiology of Dementias Group at IR Sant Pau and neurologist at Hospital de Sant Pau, explains, "These diseases cause balance problems, falls, stiffness, or difficulties with speech and movement. Many patients initially present symptoms similar to Parkinson's disease or are simply older adults with mobility issues. This often leads to underdiagnosis, as we haven't had reliable tools to determine the exact disease each patient has for years."
Understanding PSP and CBD and Their Misidentification with Parkinson's Disease
PSP and CBD are tauopathies, characterized by the abnormal accumulation of tau protein in the brain, which disrupts normal neuronal function. When tau is deposited pathologically, it causes progressive damage to various brain regions, particularly those controlling movement, balance, posture, speech, and cognitive functions. This damage explains why their initial symptoms resemble Parkinson's disease.
Dr. Ignacio Illán-Gala, a researcher in the Neurobiology of Dementias Group and neurologist at Hospital de Sant Pau, notes, "These diseases are a complex blend of Alzheimer's and Parkinson's. They share motor symptoms with Parkinson's but are caused by tau pathology, similar to Alzheimer's. The challenge has been that we lacked reliable tools to distinguish them accurately."
The Challenge of Imprecise Diagnoses and Failed Clinical Trials
For years, the lack of objective diagnostic tools has hindered treatment development for these tauopathies. Patient selection for clinical trials has relied heavily on clinical criteria, especially in early stages when symptoms are nonspecific and overlap with other diseases. This has led to biologically mixed populations in trials, reducing their ability to detect true therapeutic benefits.
This issue is particularly significant in CBD, where a significant proportion of patients actually have Alzheimer's disease. Without adequate biological filtering, clinical trial cohorts are contaminated, severely limiting their usefulness.
MRI's Role in Differentiating PSP and CBD
The study reveals that structural MRI can address a long-standing gap in tauopathies: the absence of reliable in vivo biomarkers for identifying underlying pathologies when symptoms are nonspecific. By analyzing brain atrophy patterns, researchers developed models that can estimate with high probability whether a patient has PSP or CBD, even in early disease stages.
Dr. García-Castro explains, "MRI has two key functions. Firstly, it enables more reliable early-stage diagnosis. Secondly, it allows us to objectively measure disease progression."
The study's success lies in identifying disease-specific MRI signatures based on structural changes across different brain regions. In PSP, the signature involves deep brain structures, particularly the brainstem, and selective changes in certain cortical areas. In CBD, the pattern is distinct, showing more marked involvement of cortical regions related to motor control and sensory integration.
Dr. Illán-Gala emphasizes, "Despite their clinical similarities, PSP and CBD damage the brain differently. These differences are evident on MRI, and by combining them into a signature, we can better determine the specific disease each patient has."
Feasible Clinical Trials with Real Impact for Patients
Beyond improving diagnostic accuracy, the study demonstrates that MRI can be used for longitudinal follow-up in clinical trials targeting these tauopathies. By using disease-specific MRI signatures as objective measures of disease progression, researchers can detect structural brain changes with greater sensitivity than traditional clinical scales.
Classic trial designs based on clinical variables require long follow-up periods and large sample sizes, often reaching several hundred patients. This approach is challenging for rare diseases like PSP and CBD, where recruitment is slow and costly. However, using MRI as an outcome measure significantly changes this scenario.
Analyses show that in PSP, applying disease-specific MRI signatures could reduce the number of participants needed by approximately 50% in a 12-month clinical trial compared to designs based solely on clinical scales. In CBD, where clinical and diagnostic heterogeneity is greater, the impact is even more pronounced, potentially reducing sample size by 80-85% to detect a therapeutic effect with the same statistical power.
Dr. Illán-Gala concludes, "For a clinical trial to be feasible, it must be conducted with a reasonable number of well-selected individuals and objective measures of progression. This gives us a real chance to demonstrate whether a treatment works."
Looking Ahead: Research Continuity and PERIS-Funded Initiatives
This research builds upon ongoing projects at IR Sant Pau. The center received funding from the PERIS program of the Department of Health of the Government of Catalonia to advance the early diagnosis of four-repeat tauopathies, including PSP and CBD, through the combination of plasma biomarkers and advanced imaging techniques.
This project, led by Dr. Illán-Gala, directly utilizes the published results and aims to shift diagnosis towards minimally symptomatic stages, when future disease-modifying treatments are more likely to be effective. Dr. García-Castro envisions a future where a combination of a blood test and an MRI scan allows for early and confident diagnosis of these diseases.
Dr. García-Castro concludes, "These conditions are more common than we think, but we lack the tools to detect them accurately. Improving diagnosis is the first step towards providing therapeutic options for these patients, who currently have none."
